3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Multiple Myeloma
3
Leukemia, Myeloid, Acute
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Gliosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
19
Radiotherapy
11
Bevacizumab
7
Radiation
4
Irinotecan
4
Erlotinib Hydrochloride
4
carmustine, poliferprosan 20 drug combination
3
Radiotherapy, Intensity-Modulated
3
O(6)-benzylguanine
3
Magnetic Resonance Spectroscopy
3
Carmustine
3
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
3
Vorinostat
2
Surgical Procedures, Operative
2
Radiotherapy, Conformal
2
Radiosurgery
2
Gadolinium DTPA
2
Filgrastim
2
Drug Therapy
2
Congresses as Topic
2
Cilengitide
2
Chemotherapy, Adjuvant
2
Aminolevulinic Acid
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
vitespin
1
sargramostim
1
sapanisertib
1
poly ICLC
1
plerixafor
1
picropodophyllin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Gliosarcoma
×
Immunotherapy, Adoptive
×
Clear all
NCT02664363
2023-02-17
ExCeL
Duke University
Phase 1
Terminated
3 enrolled
8 charts